Heptagon Future Trends Hedged Fund

Heptagon Future Trends Hedged Fund

Latest Nav
136.13
10 June 2024
ISIN
IE00BZBZ4842
Currency
USD
SFDR classification
Article 8
Benchmark
None
Category
Long/Short Equity - Global
Investment Style
Large Growth
Fund Size
USD7m

INVESTMENT OBJECTIVES

The Fund aims to deliver consistent and sustainable long-term returns by investing in a concentrated portfolio of global equities. The Fund also has the ability to invest in financial derivative instruments for investment purposes and to hedge against market risk.

The Fund seeks to invest in a diverse range of businesses offering exposure to the key trends which we believe will help shape the future. These trends naturally align with the Sustainable Development Goals of the United Nations and are trends which we believe will grow in importance regardless of the economy and regulation.

The Fund is highly concentrated with low levels of turnover, and is sector, size, and geography agnostic. Portfolio construction is conducted bottom-up, with an emphasis on quantitative and qualitative factors as well as ESG considerations. The Fund does not invest in areas such as gambling, weapons, or tobacco and engages in active dialogue with companies to foster good ESG practices and improve the sustainability profile of companies in the long-term. Fund Manager, Alex Gunz, has worked in finance since 1997 and prior to joining Heptagon in 2011 was a top-ranked analyst at firms including Credit Suisse and JP Morgan. 

Heptagon Future Trends – Alzheimer’s: The final healthcare frontier

Ageing populations mean Alzheimer's disease and other forms of dementia will unfortunately become more prevalent. The disease already kills more people in the US than breast cancer and prostate cancer combined. By 2050, the number of people with early onset Alzheimer’s is forecast to double versus current levels. The social and economic cost will be significant, potentially exceeding $1tr globally over the next decade. While there is no current cure for Alzheimer's, the good news is that extensive research is being focused on finding treatments for both slowing the disease and treating its symptoms. Major players such as Biogen, Eli Lilly, Novo Nordisk, Pfizer and Roche are conducting promising trials. Even with a significant drug treatment market opportunity ahead (worth at least $14bn by 2030), progress will unlikely be linear and predicting winners at this stage difficult.

Get the updates

Sign up to our monthly email newsletter for the latest fund updates, webcasts and insights.

Key stats

The below shows the information for the share class selected in the drop down box directly below the name of the fund. You can use the drop down box to view information relating to other share classes listed in the fund. A full list of all currency share classes is available on request.

Investment Team LocationLondon, UK
Active/PassiveActive
BenchmarkNone
Fund SizeUSD7m
Fund Launch09 September 2016
Fund StatusOpen to all investors
Share Class Launch09 September 2016
Share Class StatusOpen to all investors
Fund CurrencyUSD
Share Class CCYUSD
Management Fee1.5%
Min. InvestmentUSD15,000
Fund TypeUCITS
DomicileIreland
AdministratorBBH Fund Administration Services (Ireland) Ltd
DepositaryBBH Trustee Services (Ireland) Ltd
AuditorGrant Thornton
Dealing FrequencyDaily
SubscriptionsT+2
RedemptionsT+3
Risk Management
1234567
Lower RiskHigher Risk

Performance

to
Frequency

Past performance is no guide to future performance and the value of investment and income from them can fall as well as rise.

Heptagon Future Trends Equity Fund Q4 2023 Webcast

Top Ten Holdings

As of 31 May 2024
NameSectorCountryWeight %
1ASML Holding NVInformation TechnologyNetherlands6.6
2Novo Nordisk A/SHealth CareDenmark6.5
3Quanta Services, Inc.IndustrialsUnited States5.5
4First Solar, Inc.Information TechnologyUnited States5.3
5Palo Alto Networks, Inc.Information TechnologyUnited States5.2
6Xylem Inc.IndustrialsUnited States5.1
7Intuitive Surgical, Inc.Health CareUnited States4.8
8Cheniere Energy, Inc.EnergyUnited States4.8
9Arm Holdings plcInformation TechnologyJapan4.6
10Mastercard IncorporatedFinancialsUnited States4.5

Exposure Breakdowns

As of 31 May 2024
TypeFund %Benchmark %
Communication Services2.60.0
Consumer Discretionary4.00.0
Consumer Staples4.10.0
Energy4.80.0
Financials4.50.0
Health Care19.10.0
Industrials19.60.0
Information Technology25.10.0
Materials2.90.0
Real Estate8.60.0
Cash4.80.0

Fund insights

Fund Manager

Funds to consider

Global Large-Cap Growth Equity
Heptagon Future Trends Equity Fund

The Fund aims to deliver consistent and sustainable long-term returns by investing in a concentrated portfolio of global equities. The Fund seeks to invest in a diverse range of businesses offering exposure to the key trends which we believe will help shape the future. These trends naturally align with the Sustainable Development Goals of the United Nations and are trends which we believe will grow in importance regardless of the economy and regulation. The Fund is highly concentrated with low levels of turnover, and is sector, size, and geography agnostic. Portfolio construction is conducted bottom-up, with an emphasis on quantitative and qualitative factors as well as ESG considerations. The Fund does not invest in areas such as gambling, weapons, or tobacco and engages in active dialogue with companies to foster good ESG practices and improve the sustainability profile of companies in the long-term. Fund Manager, Alex Gunz, has worked in finance since 1997 and prior to joining Heptagon in 2011 was a top-ranked analyst at firms including Credit Suisse and JP Morgan.

Europe Large-Cap Growth Equity
Heptagon European Focus Equity Fund

The Fund aims to deliver long-term capital appreciation by investing in European equities. The Fund employs a high conviction, bottom-up, low turnover, research driven strategy with a focus on companies that exhibit sustainable long-term growth. Rigorous fundamental analysis is utilised to identify companies believed to have intrinsic value greater than market valuations. ESG considerations are essential to the investment process, the Fund does not invest in areas such as gambling, weapons, or tobacco and engages in active dialogue with companies to foster good ESG practices and improve the sustainability profile of companies in the long-term. The Fund also avoids commodity or energy stocks and does not generally invest in purely financial sectors as these are deemed to be closely integrated with a slow-growing economy. The Fund favours large-capitalised stocks with adequate free-float liquidity and more concentrated business models over those widely diversified. Fund Manager, Christian Diebitsch, joined Heptagon in 2014 and has been managing European Equity funds with the same investment style since 2007.

Disclaimers

Heptagon Capital Limited, Heptagon Capital LLP and its Partners disclaim any and all liability relating to these materials, including, without limitation, any express or implied representations or warranties for statements or errors contained in, and omissions from, these materials. Certain assumptions have been made, and/or parameters set, in the preparation of these materials which have resulted in the returns detailed herein, and no representation or warranty is made that any returns indicated will be achieved. Changes to assumptions or parameters may have a material impact on the returns detailed. This document should not be considered an offer to buy or sell investments. Heptagon Capital Limited has issued this communication as investment manager for Heptagon Fund ICAV, and is licenced to conduct investment services by the Malta Financial Services Authority.

Heptagon Capital LLP, acting as Distributor, is authorised and regulated in the UK by the Financial Conduct Authority.

Representative and Paying Agent in Switzerland is Société Générale, Paris, Zurich branch, Talacker 50, PO Box 1928, 8021 Zurich, Switzerland. The prospectus, the key investor information document, the Articles and the annual and semi-annual reports are available free of charge from the Swiss representative.

The results given herein are based solely upon historical fund performance as gathered and supplied by Morningstar. That past performance has not been independently verified by either Heptagon Capital Limited or Heptagon Capital LLP. It is not intended to predict or depict the future performance of any investment. Past performance is not necessarily indicative of future returns.

The information contained herein is provided for informational purposes only, is not complete, and does not contain certain material information about the funds, including important disclosures and risk factors associated with an investment in the funds. Before making an investment in any fund, prospective investors are advised to thoroughly and carefully review the fund’s private placement memorandum with their financial, legal and tax advisors to determine whether an investment is suitable for them. An investment in these funds is not suitable for all investors.

The Global Industry Classification Standard (“GICS”) was developed by and is the exclusive property and a service mark of MSCI Inc. (“MSCI”) and S&P Global Market Intelligence (“S&P”) and is licensed for use by Heptagon Fund ICAV. Neither MSCI, S&P, nor any other party involved in making or compiling the GICS or any GICS classifications makes any express or implied warranties or representations with respect to such standard or classification (or the results to be obtained by the use thereof), and all such parties hereby expressly disclaim all warranties of originality, accuracy, completeness, merchantability and fitness for a particular purpose with respect to any of such standard or classification. Without limiting any of the foregoing, in no event shall MSCI, S&P, any of their affiliates or any third party involved in making or compiling the GICS or any GICS classifications have any liability for any direct, indirect, special, punitive, consequential or any other damages (including lost profits) even if notified of the possibility of such damages.